We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

93 hedge funds and large institutions have $910M invested in Takeda Pharmaceutical in 2018 Q4 according to their latest regulatory filings, with 93 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more call options, than puts

Call options by funds: $7.49M | Put options by funds: $4.34M

6.8% more ownership

Funds ownership: 0% → 6.8% (+6.8%)

Holders
93
Holders Change
+93
Holders Change %
–
% of All Funds
2.07%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
93
Increased
–
Reduced
–
Closed
–
Calls
$7.49M
Puts
$4.34M
Net Calls
+$3.14M
Net Calls Change
+$3.14M

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$171M
2
Bank of America
Bank of America
North Carolina
+$116M
3
Citigroup
Citigroup
New York
+$111M
4
Goldman Sachs
Goldman Sachs
New York
+$86.2M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$63.7M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
TD Asset Management
26
TD Asset Management
Ontario, Canada
$3.27M +$2.14M +126,895 New
DCM
27
Diag Capital Management
New York
$2.98M +$2.99M +177,260 New
ACI
28
AMP Capital Investors
Australia
$2.02M +$2.04M +120,768 New
Comerica Bank
29
Comerica Bank
Texas
$1.99M +$1.66M +98,373 New
Ameriprise
30
Ameriprise
Minnesota
$1.9M +$1.91M +112,990 New
Envestnet Asset Management
31
Envestnet Asset Management
Illinois
$1.86M +$1.87M +110,550 New
Pacer Advisors
32
Pacer Advisors
Pennsylvania
$1.6M +$1.61M +95,192 New
Natixis Advisors
33
Natixis Advisors
Massachusetts
$1.45M +$1.45M +85,926 New
KC
34
Kepos Capital
New York
$1.26M +$1.27M +75,000 New
PC
35
PointState Capital
New York
$1.24M +$1.24M +73,600 New
Qube Research & Technologies (QRT)
36
Qube Research & Technologies (QRT)
United Kingdom
$1.17M +$1.17M +69,304 New
JP Morgan Chase
37
JP Morgan Chase
New York
$1.16M +$1.17M +69,178 New
Truist Financial
38
Truist Financial
North Carolina
$1.05M +$1.05M +62,348 New
EGPO
39
EnTrust Global Partners Offshore
New York
$1.03M +$1.03M +61,100 New
CC
40
CQS Cayman
Cayman Islands
$934K +$937K +55,500 New
CP
41
Covenant Partners
Tennessee
$900K +$903K +53,511 New
LOAMU
42
Lombard Odier Asset Management (USA)
New York
$841K +$844K +50,000 New
Geode Capital Management
43
Geode Capital Management
Massachusetts
$795K +$799K +47,323 New
RJA
44
Raymond James & Associates
Florida
$727K +$729K +43,193 New
Morgan Stanley
45
Morgan Stanley
New York
$655K +$657K +38,924 New
State Street
46
State Street
Massachusetts
$549K +$551K +32,645 New
FCH
47
Freestone Capital Holdings
Washington
$507K +$509K +30,122 New
Russell Investments Group
48
Russell Investments Group
United Kingdom
$444K +$446K +26,395 New
Bank of New York Mellon
49
Bank of New York Mellon
New York
$418K +$419K +24,844 New
WAM
50
World Asset Management
Michigan
$402K +$404K +23,923 New
1
2
3 4

TAK Hedge Fund Activity: Q4 2018 in Review

93 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2018, worth a combined $910M.

Buyers outnumbered sellers: 93 funds opened new TAK positions and 0 closed out — a net gain of 93 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $171M.

  • 93 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2018, up from 0 in Q3 2018.
  • Funds reported $910M of Takeda Pharmaceutical stock for Q4 2018.
  • 93 funds opened new Takeda Pharmaceutical positions in Q4 2018 and 0 closed out, a net change of +93 holders.
  • The largest Takeda Pharmaceutical buyer in Q4 2018 was UBS Group, an estimated $171M added.

Based on aggregated 13F filings for Q4 2018.